Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 1999Blood

A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

EAE ArchimbaudHôpital Edouard HerriotOOOliver G. OttmannCancer Genetics (United States)JYJohn A. Liu YinManchester Royal Infirmary

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Archimbaud et al. (1999) studied this question.

synapsesocial.com/papers/6a8a41be5c4c6b099dec8cdahttps://doi.org/10.1182/blood.v94.11.3694
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.1997 · 201 citations
  2. 2The Threshold for Prophylactic Platelet Transfusions in Adults with Acute Myeloid Leukemia1997 · 583 citations
  3. 3Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice1996 · 116 citations
  4. 4Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice1995 · 174 citations